Adaptimmune Therapeutics (FRA:473A) GF Score: 16/100 (As of Aug. 26, 2026) — 68% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:473A Adaptimmune Therapeutics PLC FRA:473A
16 GF Score
Price €0.16
View Full Analysis

What is Adaptimmune Therapeutics GF Score?

Adaptimmune Therapeutics FRA:473A 16 GF Score is 16 as of Aug. 26, 2026, which is 68% below its 10-year median of 50.00. GuruFocus rates FRA:473A with a GF Score™ of 16/100.

Adaptimmune Therapeutics has the GF Score of 16, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Adaptimmune Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Adaptimmune Therapeutics  (FRA:473A) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Adaptimmune Therapeutics GF Score Related Terms

FRA:473A vs BCLI, APRE, JSPR: GF Score Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's GF Score falls into.


FRA:473A
16GF Score
Adaptimmune Therapeutics PLC FRA:473A
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 16 mean?
Adaptimmune Therapeutics (FRA:473A) has a GF Score of 16 as of Aug. 26, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Adaptimmune Therapeutics and its competitors. This is 68% below median its historical median of 50.00. Over the past decade, Adaptimmune Therapeutics' GF Score has ranged from 12.00 to 70.00.
Is Adaptimmune Therapeutics' GF Score too high?
Adaptimmune Therapeutics' current GF Score of 16 is 68% below median its 10-year median of 50.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 70.00. Overall, Adaptimmune Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adaptimmune Therapeutics' GF Score compare to BCLI and APRE?
Adaptimmune Therapeutics' GF Score of 16 can be compared against companies in the Biotechnology industry. Historically, Adaptimmune Therapeutics' own GF Score has ranged from 12.00 to 70.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current GF Score is 16, which is 68% below median its own 10-year median of 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (FRA:473A) has a current GF Score of 16. The current GF Score is 16, which is 68% below median its 10-year median of 50.00. Adaptimmune Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Adaptimmune Therapeutics (FRA:473A), the current GF Score is 16 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges ADAPY:USA473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
16GF Score

Get the complete analysis for FRA:473A

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price